Table 2.

Top canonical pathways from ingenuity pathway analysis.

Group comparison	Name	p-Value	Number of genes involved	Molecules involved in pathways
HCA–Normoxia versus No HCA–Normoxia (control)	Neutrophil degranulation	1.23E−15	62	ACTR1B,ADGRE5,ALOX5,ARSA,ARSB,BST2,CAB39,CAP1,CAT,CD36,CD44,CD53,CEACAM1,CLEC4D,CLEC5A,COTL1,CPPED1,CRISPLD2,CTSS,CXCR1,CYBA,DYNC1LI1,FCGR2A,FCGR3B,FGL2,GCA,GGH,GRN,GSTP1,HPSE,HSPA6,IQGAP2,ITGAV,ITGAX,ITGB2,KCNAB2,LAMP1,LAMTOR3,LTA4H,MAN2B1,OLR1,PECAM1,PGLYRP1,PRDX4,PSAP,PSMA5,PSMD14,QSOX1,RAC1,RHOA,RHOG,RNASE3,SERPINA1,SIRPB1,SLC11A1,STK10,STOM,SVIP,TLR2,TMT1A,TXNDC5,VAT1
	Mitochondrial dysfunction	2.84E−10	42	ACADL,ACO2,APH1A,APP,ATP1B1,ATP5MC3,ATP5ME,ATP5MGL,ATP5PB,ATP5PO,BID,CAMK2D,COX5A,COX6B1,COX7A1,COX7A2,COX8A,COXFA4,CYCS,DLD,FIS1,GPD2,GPX3,GSTP1,ITPR1,LRRK2,MCU,MYH9,NDUFA13,NDUFA6,NDUFAB1,NDUFB5,NDUFB9,NDUFV3,PIK3C2B,PIK3R6,PPARG,PRKACA,PRKN,SDHD,UQCRC1,UQCRFS1
	Oxidative phosphorylation	1.29E−09	21	ATP5MC3,ATP5ME,ATP5MGL,ATP5PB,ATP5PO,COX5A,COX6B1,COX7A1,COX7A2,COX8A,COXFA4,CYCS,NDUFA13,NDUFA6,NDUFAB1,NDUFB5,NDUFB9,NDUFV3,SDHD,UQCRC1,UQCRFS1
	Respiratory electron transport	1.88E−08	18	COX5A,COX6B1,COX7A1,COX7A2,COX8A,COXFA4,CYCS,ETFB,ETFDH,NDUFA13,NDUFA6,NDUFAB1,NDUFB5,NDUFB9,NDUFV3,SDHD,UQCRC1,UQCRFS1
	Class I MHC mediated antigen processing and presentation	7.01E−08	40	ANAPC11,ASB8,BCAP31,CD36,CTSS,CUL1,CYBA,FBXL4,FBXO31,ITGAV,KLHL2,KLHL20,KLHL21,KLHL22,LNPEP,NCF2,PJA1,PRKN,PSMA5,PSMA6,PSMB10,PSMB2,PSMB4,PSMB8,PSMB9,PSMD14,PSMD5,RBX1,RNF217,SEC13,SEC61B,SH3RF1,TLR1,TLR2,TLR6,TRIM69,UBA6,UBE2C,UBE2J2,UBE2W
No HCA–Hyperoxia versus No HCA–Normoxia (control)	SUMOylation of DNA damage response and repair proteins	8.77E−05	8	EID3, NUP85, PHC2, RAE1, SMC1A, TPR, XPC, XRCC4
	Sirtuin signaling pathway	1.19E−04	16	AGTRAP, ATG16L1, ATP5F1C, CXCL8, GADD45B, GTF3C2,IDH2, NDUFA10, NDUFA11, NDUFB10, PPARG, TIMM23, TUBA1A, UCP2, XPA,XPC
	FXR/RXR activation	2.57E−04	12	CNTF, CXCL8, DDIT3, GCLM, GSTK1, IFNG, IL36RN,MAPK9, NLRP3, PPARG, PRKAB1, TXNIP
	Retinol biosynthesis	4.36E−04	6	AADAC, CES2, CES5A, DAGLB, DHRS7, RDH10
	TREM-1 signaling	5.96E−04	7	CD83, CD86, CXCL8, ITGAX, NLRP3, TLR6, TLR8
HCA–Hyperoxia versus No HCA–Normoxia (control)	Neutrophil degranulation	3.14E−15	73	ACP3,APEH,ARSA,ARSB,CAP1,CD36,CD44,CD58,CEACAM1,CLEC4D,CLEC5A,COTL1,CPNE3,CRISPLD2,CYBA,DEGS1,DNAJC3,DOCK2,DOK3,DYNC1LI1,FCAR,FCGR2A,FCGR3B,GGH,GLA,GM2,GMFG,GOLGA7,GPR84,GSTP1,HGSNAT,HPSE,HSPA6,IMPDH2,IQGAP2,ITGAV,ITGAX,KCNAB2,LAMP1,LAMTOR3,LGALS3,LTA4H,MAN2B1,MCEMP1,MGAM,MGST1,MMP8,MOSPD2,OLR1,P2RX1,PGLYRP1,PGM1,PLAUR,PLEKHO2,PRDX4,PSAP,PSMA5,PSMB1,PSMD7,PTPN6,QSOX1,RAB7A,RAC1,RAP2B,RHOA,RHOG,S100A11,SDCBP,SIRPA,SIRPB1,SLC11A1,TLR2,TOM1
	Class I MHC mediated antigen processing and presentation	2.87E−12	58	ANAPC11,ANAPC7,AREL1,ASB8,BCAP31,BLMH,BTRC,CALR,CD3,CHUK,CUL5,CYBA,ELOC,FBXO21,FBXW7,HSPA5,ITGAV,KEAP1,KLHL2,KLHL20,LONRF1,MRC2,NCF2,PSMA3,PSMA5,PSMA6,PSMB1,PSMB10,PSMB4,PSMB5,PSMB8,PSMC6,PSMD4,PSMD7,PSMD8,RBX1,RNF114,RNF41,SEC13,SEC22B,SEC61B,SH3RF1,SPSB1,TLR2,TLR4,TLR6,TRIM69,UBC,UBE2C,UBE2J1,UBE2J2,UBE2 K,UBE2Q2,UBE2R2,UBE2V1,UBE2W,UBE2Z,UNKL
	Protein Ubiquitination Pathway	6.56E−12	47	ANAPC11,BAP1,BTRC,CBL,DNAJB11,DNAJB12,DNAJB5,DNAJC21,DNAJC28,DNAJC3,DNAJC7,ELOC,FBXW7,HSCB,HSPA5,HSPA6,HSPD1,MDM2,PSMA3,PSMA5,PSMA6,PSMB1,PSMB10,PSMB4,PSMB5,PSMB8,PSMC6,PSMD4,PSMD7,PSMD8,RBX1,SUGT1,UBC,UBE2C,UBE2I,UBE2J1,UBE2J2,UBE2 K,UBE2Q2,UBE2R2,UBE2V1,UBE2W,UBE2Z,USO1,USP18,USP2,USP32
	RHO GTPase cycle	2.76E−10	60	ABI1,ABR,ACTG1,ADD3,ALDH3A2,ARAP1,ARFGAP3,ARHGAP11B,ARHGAP18,ARHGAP24,ARHGAP26,ARHGEF2,ARHGEF6,BAIAP2,BCAP31,BLTP3B,CCT6A,CDC42EP3,COPS4,CPD,CYBA,DBT,DNMBP,DOCK1,DOCK10,DOCK2,DOCK5,DOCK7,EMD,FARP2,FGD3,FGD4,FMNL3,GIT1,GOLGA8 K (includes others), IQGAP2,LCK,MOSPD2,MTX1,MYO6, MYO9B,NCF2,RAB7A, RAC1,RAPGEF1,RHOA,RHOG,RHOQ, SH3RF1,SHKBP1,SOWAHC,TAOK3,TEX2,TFRC,TRIO,VIM,WASL,WDR11,WDR6,WDR91
	Activation of gene expression by SREBF (SREBP)	3.05E−10	16	ACACA,CYP51A1,DHCR7,FDFT1,FDPS,GGPS1,HELZ2,HMGCR,IDI1,LSS,MTF1,NCOA6,SC5D,SCD,SQLE,SREBF2